XR5944: A potent inhibitor of estrogen receptors

Molecular Cancer Therapeutics

Volumn 6, Issue 1, 2007, Pages 213-219

  Punchihewa, Chandanamali ^a   De Alba, Adrian ^a   Sidell, Neil ^c   Yang, Danzhou ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; CIS ACTING ELEMENT; DACTINOMYCIN; DNA; DNA TOPOISOMERASE INHIBITOR; DOUBLE STRANDED DNA; ESTROGEN RECEPTOR; LUCIFERASE; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; XR 5944;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CELL CULTURE; CELL NUCLEUS; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA BINDING; DNA SEQUENCE; DRUG POTENCY; DRUG RESISTANCE; DRUG SPECIFICITY; DRUG STRUCTURE; ESTROGEN RESPONSIVE ELEMENT; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; REPORTER GENE; TRANSACTIVATION;

ANTINEOPLASTIC AGENTS; DACTINOMYCIN; DNA, NEOPLASM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; LUCIFERASES; PHENAZINES; RECEPTORS, ESTROGEN; RESPONSE ELEMENTS; SP1 TRANSCRIPTION FACTOR; SUBSTRATE SPECIFICITY; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 33846847637     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0392     Document Type: Article

References (43)

1. Key T, Appleby P, Barnes I, Reeves G. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
2. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999;81:339-44.
3. Schairer C, Gail M, Byrne C, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 1999;91:264-70.
4. Berger T, Brigl M, Herrmann JIM, et al. The apoptosis mediator mDAP-3 is a novel member of a conserved family of mitochondrial proteins. J Cell Sci 2000;113:3603-12.
5. Jensen EV, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 1962;18:387-414.
6. Pearce ST, Jordan VC. The biological role of estrogen receptors α and β in cancer. Crit Rev Oncol Hematol 2004;50:3-22.
7. Dixon JM, Bundred N. Aromatase inhibitors for early breast cancer therapy: a choice of effective treatment strategies. Eur J Surg Oncol 2006;32:123-5.
8. Kurebayashi J. Resistance to endocrine therapy in breast cancer. Cancer Chemother Pharmacol 2005;56:s39-46.
9. Byers SA, Schafer B, Sappal DS, Brown J, Price DH. The antiproliferative agent MLN944 preferentially inhibits transcription. Mol Cancer Ther 2005;4:1260-7.
10. Gamage SA, Spicer JA, Finlay GJ, et al. Dicationic bis(9-methyl-phenazine-l-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs. J Med Chem 2001;44:1407-15.
11. Finlay GJ, Riou JF, Baguley BC. From amsacrine to DACA (N-[2-dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur J Cancer 1996;32A:708-14.
12. Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs 2002; 13:15-28.
13. Vicker N, Burgess L, Chuckowree IS, et al. Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents. J Med Chem 2002;45:721-39.
14. Stewart AJ, Mistry P, Dangerfield W, et al, Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs 2001;12:359-67.
15. Sappal DS, McClendon AK, Fleming JA, et al. Biological characterization of MLN944: a potent DNA binding agent. Mol Cancer Ther 2004;3:47-58.
16. Di Nicolantonio F, Knight LA, Whitehouse PA, et al. The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples. Mol Cancer Ther 2004; 3:1631-7.
17. Harris SM, Scott JA, Brown JL, Charton PA, Mistry P. Preclinical antitumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinoma. Anticancer Drugs 2005; 16:945-51.
18. Harris SM, Mistry P, Freathy C, Brown JL, Charlton PA. Antiturnour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines. Br J Cancer 2005; 92:722-8.
19. Dai J, Punchilhewa C, Mistry P, Doi AT, Yang D. Novel DNA bis-intercalation by VILN944, a potent clinical bisphenazine anticancer drug. J Biol Chem 2004; 279:46096-103.
20. Beato M, Chalepakis G, Schauer M, Slater EP. DNA regulatory elements for steroid hormones. J Steroid Biochem Mol Biol 1989;32:737-47.
21. Lannigan DA, Notides AC. Estrogen regulation of transcription. Prog Clin Biol Res 1990;322:187-97.
22. Nunez SB, Medin JA, Braissant O, et al. Retinoid X receptor and peroxisome proliferator-activated receptor activate an estrogen responsive gene independent of the estrogen receptor. Mol Cell Enclocrinol 1997;127:27-40.
23. Sawatsri S, Samid D, Malkapuram S, Sidell N. Inhibition of estrogen-dependent breast cell responses with phenylacetate. Int J Cancer 2001;93:687-92.
24. Biggs JR, Kudlow JE, Kraft AS. The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. J Biol Chem 1996; 271:901-6.
25. Mi ZH, Malak H, Burke TG. Reduced albumin-binding promotes the stability and activity of topotecan in human blood. Biochemistry 1995;34:13722-8.
26. Reich E, Goldberg IH. Actinomycin and nucleic acid function. Prog Nucleic Acid Res Mol Biol 1964;3:183-234.
27. Sentenac A, Simon EJ, Fromageot P. Initiation of chains by RNA polymerase and the effects of inhibitors studied by a direct filtration technique. Biochim Biophys Acta 1968; 161:299-308.
28. Nutter LM, Ngo ED, Abul-Hajj YJ. Characterization of DNA damage induced by 3,4-estrone-o-quinone in human cells. J Biol Chem 199 1;266:16380-6.
29. Telang NIT, Suto A, Wong GY, Osborne VIP, Bradlow HL. Induction by estrogen metabolite 16 α-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 1992;84:634-8.
30. Liehr JG, Gladek A, Macatee T, Randerath E, Randerath K. DNA adduct formation in liver and kidney of male Syrian hamsters treated with estrogen and/or α-naphthoflavone. Carcinogenesis 1991;12:385-9.
31. DeSombre ER, Shafii B, Hanson RN, Kuivanen PC, Hughes A. Estrogen receptor-directed radiotoxicity with Auger electrons: specificity and mean lethal dose. Cancer Res 1992;52:5752-8.
32. Snyder RD, Brown JE. Evidence for and role of the dimethylamino group in tamoxifen DNA intercalation in intact Chinese hamster V79 cells. Drug Chem Toxicol 2002;25:473-9.
33. Hendry LB, Mahesh VB. A putative step in steroid hormone action involves insertion of steroid ligands into DNA facilitated by receptor proteins. J Steroid Biochem Mol Biol 1995;55:173-83.
34. Hendry LB, Bransome ED, Jr., Mahesh VB. The ligand insertion hypothesis in the genomic action of steroid hormones. J Steroid Biochem Mol Biol 1998;65:75-89.
35. Mahesh VB, Lewis WR, Cannady WE, et al. Gene based pharmacophores for drug design. Med Chem Res 2001;10:440-55.
36. Hendry LB, Chu CK, Copland JA, Mahesh VB. Antiestrogenic piperidinediones designed prospectively using computer graphics and energy calculations of DNA-ligand complexes. J Steroid Biochem Mol Biol 1994;48:495-505.
37. Sidell N, Tanmahasamut P, Ewing DE, Hendry LB. Transcriptional inhibition of the estrogen response element by antiestrogenic piperidinediones correlates with intercalation into DNA measured by energy calculations. J Steroid Biochern Mol Biol 2005;96:335-45.
38. Michalides R, Griekspoor A, Balkenende A, et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer. Cancer Cell 2004;5:597-605.
39. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J Biol Chem 2001;276:9817-24.
40. Weis KE, Ekena K, Thomas JA, Lazennec G, Katzenellenbogen BS. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol 1996;10:1388-98.
41. Daffada AA, Johnston SR, Smith IE, Detre S, King N, Dowsett M. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res 1995;55:288-93.
42. Bergman L, Beelen VIL, Gallee VIP, Hollema H, Benraadt J, van Leeuwen FE; Comprehensive Cancer Centres' ALERT Group. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Assessment of Liver and Endometrial cancer Risk following Tannoxifen. Lancet 2000;356:881-7.
43. Sismondi P, Biglia N, Volpi E, Giai M, de Grandis T. Tamoxifen and endometrial cancer. Ann N Y Acad Sci 1994;734:310-21.